Your Feed

Filter by
See content from
Back to the latest
Avatar
jamorsch
Multiple Myeloma Discussion • September 24, 2024
Sharing Experiences With Motixafortide?
AI-generated title
I am scheduled for stem cell collection at the end of October. My doctor has suggested using Motixafortide (instead of Mozobil) for mobilization. Does anyone have any experience with this drug? I understand there are some unpleasant side effects.
Avatar
TimJohnson
Multiple Myeloma Discussion • September 24, 2024
Weird Hair Question: Cowlick From Treatment?
AI-generated title
Somewhat embarrassing self-image question... I've been on DRVd induction therapy since the end of March of this year and a cow lick on the back of my head has reappeared. It's been gone since I was in 3rd or 4th grade but now it's back. I'm wondering if this is just a normal aging thing (now 66yo) or if it's weird side effect of the drugs. Anyone else experienced anything like this?
Avatar
Iliana • Admin
Multiple Myeloma Discussion • September 24, 2024
New Clinical Trial for Relapsed Myeloma
AI-generated title
A phase III study is open comparing a new drug called mezigdomide (CC-92480), carfilzomib and dexamethasone vs. carfilzomib and dexamethasone. Mezigdomide is part of a new class of drugs called CELMoDs. Study participants who have relapsed or refractory myeloma, at least one prior line of therapy (that included either lenalidomide or 2 cycles of an anti-CD28 monoclonal antibody) are welcome to join. Learn more: https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT05552976?cid=s_2839275
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | BMS Clinical Trials

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | BMS Clinical Trials

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT05552976?cid=s_2839275
Avatar
Julia
Multiple Myeloma Discussion • September 24, 2024
New Allergies From Donor Cells?
AI-generated title
Good morning. I have a patient that I'm chatting with. She had a donor stem cell transplant. She now feels as if she has developed allergies and wonders if it is possible to have gotten them from her donor cells? Has anyone heard if this is possible?
Avatar
shaila02784@yahoo.com
Multiple Myeloma Discussion • September 24, 2024
Humerus Rod Surgery: What to Expect?
AI-generated title
Hi, due to my myeloma tumor progression in my right upper arm/humerus and how the tumor affected the bone, the orthopedic surgeon recommending to go through surgery which is putting a rod inside. Has anyone went through this kind of surgery? Would love to hear any pros and cons the individual has experienced. Thank you!
Avatar
Iliana • Admin
Multiple Myeloma Discussion • September 23, 2024
Learn About a New CAR T Trial for Myeloma
AI-generated title
CAR T therapy is a growing option for multiple myeloma patients and investigational CAR T treatments and targets are now in development. Investigational treatments using different targets could help patients who have relapsed after standard of care myeloma therapies including the newest BCMA-targeting immunotherapies.   The QUINTESSENTIAL Phase II clinical trial aims to test the impact of an investigational CAR T therapy called BMS-986393, which targets GPRC5D, in relapsed or refractory multiple myeloma patients.  This multi-center study is open in over 35 locations. Please click the link to learn more or to join the study: https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT06297226?cid=s_2839282 Funded by Bristol Myers Squibb
Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | BMS Clinical Trials

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | BMS Clinical Trials

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.

https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT06297226?cid=s_2839282
Avatar
Iliana • Admin
Multiple Myeloma Discussion • September 23, 2024
A New Study Exploring CAR T After Transplant
AI-generated title
A research study is being performed with the goal of improving outcomes for newly diagnosed multiple myeloma patients whose myeloma hasn’t responded optimally to traditional induction and stem cell transplant therapy.  Lenalidomide is traditionally used as a maintenance therapy to deepen responses after transplant, but this study aims to test whether adding CAR T therapy can further improve responses and outcomes.  Learn more about this study at: https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT06045806?cid=s_2839286 Funded by Bristol Myers Squibb.
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation | BMS Clinical Trials

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation | BMS Clinical Trials

Explore Potential treatments for adults with newly diagnosed Multiple Myeloma who didn't respond well after a stem cell transplant. See if you qualify and learn how to join a Clinical Study at Bristol Myers Squibb

https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT06045806?cid=s_2839286
Avatar
Lindsay
Multiple Myeloma Discussion • September 23, 2024
Advice & Hopeful Stories for IgA Kappa?
AI-generated title
Hello, does anyone have any advice/suggestions on IGAKAPPA myeloma with it being 70%. ? If there any hopeful stories as well as holistic stories I would greatly appreciate to hear them. Thank you
Avatar
BarbaraH
Multiple Myeloma Discussion • September 23, 2024
D-VRd With Only One Kidney: Experiences?
AI-generated title
Hello! I’m pretty newly diagnosed High-Risk SMM with the complication of only having one kidney. They’re discussing starting me on D-VRd & I’m just wondering if anyone else here has kidney issues & is on this regime & how it’s working out for them? They did mention modifying the dose of one of the meds in the Quad in order to lessen the burden on the kidney. Any info anyone has would be great ~ thanks!
Avatar
amjadali
Multiple Myeloma Discussion • September 21, 2024
Returning to Swimming During Treatment?
AI-generated title
Question about swimming after diagnosis of multiple myeloma. My wife was diagnosed with multiple myeloma in July 2024. She is going thru induction therapy with quad regimen with possibility of stem cell transplant in Dec 2024. She loves swimming and has been swimming for exercise for years. We are wondering if she will be able to swim again? We would like feed back from other myeloma patients about this issue. Thanks.
Avatar
azbobmorrison
Multiple Myeloma Discussion • September 21, 2024
Pre-SCT Test Validity: How Long Do They Last?
AI-generated title
How long do the results of Urine and Blood Tests last for considering stem cell transplant? I have had all the tests listed since June of 2024 and I am going in for consultation on Sept 25th and was wondering if I had to repeat test.